Latest Articles
-
Anthropic’s Big Software Reset: Winners & Losers
In early February 2026, the tech sector saw a sharp and sudden valuation reset, with nearly $300 billion in market capitalization wiped out in roughly a single trading day. The declines were concentrated in software, data services, and IT outsour...
-
A Money Making Strategy for Qualcomm’s Memory Crisis
Qualcomm (QCOM) shares plunged nearly 9% on February 5, 2026 to $136 because of a dramatic shortfall in forward guidance. The core issue is a global DRAM shortage and surging memory prices, driven by high demand for AI data centers, which has for...
-
McKesson Stock’s 17% Earnings Rip: Is The “Boring” Distributor Dead?
On Wednesday, McKesson (MCK) shattered its “boring middleman” reputation. The stock jumped 17% to a new all-time high of $958 on volume nearly 6x the daily average. This wasn’t just a short squeeze. It was a structural re-rating...
-
Should Estee Lauder Stock Investors Panic?
The beauty industry was jolted yesterday as shares of Estée Lauder (EL) plummeted nearly 20%, following the Q2 FY26 earnings release. While the company reported a beat on headline earnings and revenue, the forward-looking commentary painted a s...
-
This Strategy Pays You 10.0% While Lining Up LRCX at Bargain Prices
At about $213.31 a share, Lam Research (LRCX) is trading about 14% below its 52-week high. Do you think LRCX stock is a good long-term bet at current levels? What about at a 40% discount at about $128 per share? If you think that is a steal and ...
-
Catalysts That Could Propel UnitedHealth Stock to the Moon
UnitedHealth has demonstrated significant rally potential, with multiple instances of >30% gains in under two months recorded in key years 2010, 2019, 2020, 2021, and 2025. Notably, it achieved >50% rallies twice in 2020 and 2025. If past p...
-
What Could Go Wrong With Intel Stock?
Intel (INTC) has stumbled before. Its stock has plunged more than 30% within a span of less than 2 months on 3 occasions in recent years, wiping out billions in market value and erasing massive gains in a single correction. If history is any guid...
-
Cash Machine Trading Cheap – Docusign Stock Set to Run?
We think Docusign (DOCU) stock is worth a look: It is growing, producing cash, and available at a significant valuation discount . Companies like this can use cash to fuel additional revenue growth, or simply pay their shareholders through divide...
-
Applied Materials Stock’s Winning Streak May Not Be Over Yet
We think Applied Materials (AMAT) stock might be a good investment candidate. Why? Because you get a strong margin, a low-debt capital structure, and strong momentum – with room to run as the stock is meaningfully below its 52-week high ....
-
T-Mobile US Stock Now 21% Cheaper, Time To Buy
T-Mobile US (TMUS) stock might be a good buy now. Why? Because you get high margins —reflective of pricing power and cash generation capacity—for a discounted price . Companies like this generate consistent, predictable profits and cash flows, wh...
-
Has Accenture Stock Quietly Become a Value Opportunity?
We think Accenture (ACN) stock could be a good value buy . It is currently trading lower than average valuation, is growing, even though modestly, and has strong margins to go with its low valuation. Buying stocks with low valuations or trading ...
-
Strong Cash Yield: Is Elevance Health Stock A Buy?
Elevance Health (ELV) could be a good pick for your portfolio, with its high cash yield, good fundamentals, and discounted valuation . Companies like this can use cash to fuel additional revenue growth, or simply pay their shareholders through di...
-
Buy or Sell Johnson & Johnson Stock?
Johnson & Johnson (JNJ) stock has jumped 16% during the past month, and is currently trading at $237.79. We believe there are only a couple of things to fear in JNJ stock given its overall Strong operating performance and financial condition...
-
Phibro Animal Health Stock To $35?
Phibro Animal Health (PAHC) stock has jumped 22% during the past day, and is currently trading at $50.00. Our multi-factor assessment suggests that it may be time to sell PAHC stock. We have, overall, a pessimistic view of the stock, and a price ...
-
Why BSX, RMD Could Outperform IDEXX Laboratories Stock
BSX, RMD are IDEXX Laboratories’s peers in Health Care Equipment industry that have: 1) Lower valuation (P/OpInc) compared to IDEXX Laboratories stock 2) But higher revenue and operating income growth This disconnect between valuation and...
